S. Hurvitz

发表

Triple-negative breast cancer: advancements in characterization and treatment approach

S. Hurvitz, M. Mead, 2015, Current opinion in obstetrics & gynecology.

Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma

T. Habermann, S. Ansell, I. Lowy, 2009, Clinical Cancer Research.

Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.

J. Baselga, H. Iwata, B. Sankaran, 2018, European journal of cancer.

Phase II study of Roche ’ s giredestrant meets primary endpoint in the most frequently diagnosed type of breast cancer

S. Hurvitz, 2021 .

A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC).

H. Wildiers, J. Jassem, L. Dirix, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.

S. Loi, H. Rugo, M. Robson, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

E. Perez, V. Valero, H. Rugo, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II/III trial of active immunotherapy with OPT-822/OPT-821 in patients with metastatic breast cancer.

Chiun-Sheng Huang, Ming-Feng Hou, Chi-Huey Wong, 2016 .

NatHER: protocol for systematic evaluation of trends in survival among patients with HER2-positive advanced breast cancer

M. Beattie, B. Kalesan, S. Hurvitz, 2015, Systematic Reviews.

Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE).

W. Symmans, V. Valero, Chiun-Sheng Huang, 2016 .

Abstract S6-01:PIK3CAstatus in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial:

J. Baselga, H. Iwata, W. Jonat, 2016 .

Sulfhydryl-Based Tumor Antigen-Carrier Protein Conjugates Stimulate Superior Antitumor Immunity against B Cell Lymphomas1

J. Timmerman, S. Hurvitz, D. Betting, 2008, The Journal of Immunology.

Successful treatment with cyclophosphamide of life-threatening diffuse hemangiomatosis involving the liver.

S. Hurvitz, M. Sanford, C. Hurvitz, 2000, Journal of pediatric hematology/oncology.

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

E. Perez, L. Dirix, S. Hurvitz, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.

M. Beckmann, W. Symmans, V. Valero, 2018, The Lancet. Oncology.

Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer

B. Comin-Anduix, J. Sayre, S. Demaria, 2018, Clinical Cancer Research.

Bringing Safe and Effective Therapies to Premenopausal Women with Breast Cancer: Efforts to Broaden Eligibility Criteria.

F. Cardoso, M. Goetz, M. Regan, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis

M. Piccart, L. Carey, A. Bardia, 2022, NPJ breast cancer.

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

A. Bardia, H. Rugo, R. Leon-Ferre, 2022, Breast Cancer Research and Treatment.

Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

Amy M. Sitapati, W. Gradishar, R. Aft, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Breast Cancer, Version 3.2022

Amy M. Sitapati, W. Gradishar, R. Aft, 2022 .

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.

M. Piccart, L. Carey, A. Bardia, 2021, The New England journal of medicine.

Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer.

L. Carey, A. Bardia, H. Rugo, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer

Chiun-Sheng Huang, D. Slamon, M. Press, 2019, Clinical Cancer Research.

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.

H. Wildiers, J. Jassem, L. Dirix, 2015, Breast.

Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer

E. Perez, L. Amler, L. Gianni, 2014, Breast Cancer Research.

A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01).

F. Kabbinavar, D. Slamon, J. Glaspy, 2010, Clinical breast cancer.

Combination of Cyclophosphamide, Rituximab, and Intratumoral CpG Oligodeoxynucleotide Successfully Eradicates Established B cell Lymphoma

N. Van Rooijen, J. Timmerman, S. Hurvitz, 2012, Journal of immunotherapy.

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.

W. Eiermann, H. Rugo, Y. Im, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

W. Eiermann, H. Rugo, L. Fehrenbacher, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

R. Greil, E. Winer, S. Loi, 2019, The New England journal of medicine.

Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.

Sung-Bae Kim, W. Gradishar, N. Masuda, 2019, Journal of Clinical Oncology.

Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer

J. S. Kim, M. Espié, Sung-Bae Kim, 2021, Breast Cancer Research and Treatment.

Estrogen Receptor (ER)α-regulated Lipocalin 2 Expression in Adipose Tissue Links Obesity with Breast Cancer Progression*

H. Christofk, A. Hevener, K. Korach, 2014, The Journal of Biological Chemistry.

Role of age and health in treatment recommendations for older adults with breast cancer: the perspective of oncologists and primary care providers.

A. Naeim, S. Bhatia, J. Mortimer, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry

H. Rugo, S. Swain, M. Cobleigh, 2021, Breast Cancer Research and Treatment.

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study

P. Fasching, W. Symmans, V. Valero, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Edinburgh Research Explorer Tucatinib, Trastuzumab and Capecitabine for HER2+ Metastatic Breast Cancer

S. Loi, N. Lin, C. Anders, 2019 .

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer.

E. Perez, I. Bondarenko, A. Brufsky, 2009 .

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Sung-Bae Kim, W. Gradishar, M. Yamaguchi, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SERUM THYROTROPIN CONCENTRATIONS ARE NOT PREDICTIVE OF AGGRESSIVE BREAST CANCER BIOLOGY IN EUTHYROID INDIVIDUALS.

Ning Li, A. Leung, M. Yeh, 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy

J. Brugge, J. Dering, D. Slamon, 2021, medRxiv.

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy

F. André, M. Campone, J. Soria, 2013, Breast Cancer Research and Treatment.

Effect and Efficiency of an Embedded Palliative Care Nurse Practitioner in an Oncology Clinic.

N. Wenger, A. Coscarelli, S. Hurvitz, 2017, Journal of oncology practice.

Anthracycline Use in ERBB2-Positive Breast Cancer: It Is Time to Re-TRAIN.

S. Hurvitz, 2021, JAMA oncology.

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer

S. Verma, D. Tripathy, D. Yardley, 2016, BMC Cancer.

Afatinib in the treatment of breast cancer

N. Harbeck, S. Hurvitz, R. Shatsky, 2014, Expert opinion on investigational drugs.

Relationship between HER 2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM 4450 g : a randomized phase II study of patients with previously untreated HER 2-positive metastatic breast cancer

E. Perez, L. Amler, L. Gianni, 2014 .

P. Ganz, J. Bower, C. Crespi, 2022, NPJ breast cancer.

Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial

L. Chow, A. Bardia, F. Cardoso, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy

W. Eiermann, H. Rugo, I. C. Tudor, 2019, JNCI cancer spectrum.

Talazoparib in Patients with a Germline BRCA‐Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial

H. Rugo, I. C. Tudor, J. Chakrabarti, 2019, The oncologist.

A look at current and potential treatment approaches for hormone receptor‐positive, HER2‐negative early breast cancer

H. Burstein, N. Harbeck, S. Johnston, 2022, Cancer.

Acute and Chronic Effects of Adjuvant Therapy on Inflammatory Markers in Breast Cancer Patients

M. Irwin, P. Ganz, J. Bower, 2022, JNCI cancer spectrum.

Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?

E. Winer, S. Schnitt, H. Rugo, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.

Chiun-Sheng Huang, Bing-he Xu, N. Harbeck, 2016, The Lancet. Oncology.

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.

L. Chow, A. Bardia, N. Harbeck, 2019, The New England journal of medicine.

A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer.

J. Baselga, H. Rugo, F. André, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

M. Piccart, L. Carey, A. Bardia, 2022, npj Breast Cancer.

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

S. Loi, N. Lin, G. Curigliano, 2019, The New England journal of medicine.

Cancer Therapy : Clinical Phase I Study of Ipilimumab , an Anti – CTLA-4 Monoclonal Antibody , in Patients with Relapsed and Refractory B-Cell Non – Hodgkin Lymphoma

T. Habermann, S. Ansell, I. Lowy, 2009 .

The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies

S. Hurvitz, R. Kakkar, 2012, Therapeutic advances in medical oncology.

Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial.

P. Fasching, H. Rugo, M. Robson, 2018, European journal of cancer.

Study CTKI258A2202: A multicenter, open-label phase II trial of dovitinib (TKI258) in FGFR1-amplified and nonamplified HER2-negative metastatic breast cancer.

M. Ellis, J. Baselga, H. Rugo, 2010 .

Pooled safety analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2- advanced breast cancer (ABC).

G. Hortobagyi, F. Esteva, D. Tripathy, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs

H. Rugo, S. Swain, M. Cobleigh, 2018, Clinical Cancer Research.

Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3.

C. Isaacs, F. André, M. Riester, 2015 .

Advances in the use of PARP inhibitor therapy for breast cancer

S. Hurvitz, Kelly E McCann, 2018, Drugs in context.

Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study.

H. Burris, D. Yardley, G. Jerusalem, 2018 .

Clinical features of pseudocirrhosis in metastatic breast cancer

M. Douek, S. Hurvitz, Phillip S. Ge, 2019, Breast Cancer Research and Treatment.

A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity

Lance G. Laing, C. Lange, I. Macneil, 2016, Oncotarget.

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.

M. Espié, Sung-Bae Kim, A. Schneeweiss, 2015, The Lancet. Oncology.

Primary dural marginal zone lymphoma in a woman with inflammatory breast cancer.

J. Said, S. Hurvitz, Heather S. Lewin, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

H. Rugo, J. Hopkins, Miguel Martín, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer

R. Crosby, S. Hurvitz, S. Mathias, 2013, Breast Cancer Research and Treatment.

Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens

Sung-Bae Kim, W. Gradishar, R. Bose, 2021, Breast Cancer Research and Treatment.

Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

S. Hilsenbeck, R. Schiff, J. Reis-Filho, 2021, Clinical Cancer Research.

A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)

P. Fasching, H. Rugo, M. Robson, 2018, Clinical Cancer Research.

Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer

D. Slamon, S. Hurvitz, K. Rose, 2020, Breast Cancer Research.

Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician's choice chemotherapy treatment (PCT): A focus on the EMBRACA triple negative (TNBC) subpopulation.

H. Rugo, S. Hurvitz, A. Hannah, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Patient-reported outcomes (PROs) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA HR+/HER2- subpopulation

H. Rugo, J. Litton, S. Hurvitz, 2018, The Breast.

Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial.

Sung-Bae Kim, J. Baselga, A. Bardia, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) in combination with either tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with HR+, HER2- advanced breast cancer (aBC): MONALEESA-7.

L. Chow, A. Bardia, N. Harbeck, 2015 .

Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis

A. Schneeweiss, S. Swain, C. Jackisch, 2022, Cancers.

Increasing Appropriate BRCA1/2 Mutation Testing: The Role of Family History Documentation and Genetic Counseling in a Multidisciplinary Clinic

A. Kishan, A. Kusske, S. McCloskey, 2016, Annals of Surgical Oncology.

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial.

R. Bose, H. Rugo, D. Tripathy, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial

A. Chien, N. Iannotti, C. Barcenas, 2020 .

Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab

Y. Fujiwara, M. Colleoni, V. Hanes, 2019, Targeted Oncology.

M. Piccart, L. Carey, A. Bardia, 2022, European journal of cancer.

Talazoparib in Patients with a Germline BRCA‐Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial

H. Rugo, I. C. Tudor, J. Chakrabarti, 2019, The oncologist.

Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer

L. Esserman, H. Rugo, R. D'Agostino, 2017, JAMA.

Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.

A. Bardia, F. Meric-Bernstam, F. Penault-Llorca, 2016, Breast.

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

W. Eiermann, H. Rugo, I. C. Tudor, 2018, The New England journal of medicine.

Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO).

P. Fasching, H. Rugo, M. Robson, 2017 .

Analysis of germline BRCA1/2 mutated (gBRCAmut) hormone receptor-positive (HR+) and triple negative breast cancer (TNBC) treated with talazoparib (TALA).

W. Eiermann, H. Rugo, I. C. Tudor, 2018 .

ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer.

S. Loi, Yeon-Hee Park, N. Harbeck, 2022, Future oncology.

Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens

S. Ramsey, S. Sullivan, R. Hansen, 2014, SpringerPlus.

HER2DX: a tool that might inform treatment choices for HER2-positive breast cancer.

S. Hurvitz, 2020, The Lancet. Oncology.

Breast cancer: The debate over post-mastectomy radiotherapy should continue

S. Hurvitz, C. Oliai, 2015, Nature Reviews Clinical Oncology.

Phase II randomized trial of a non-steroidal mouth wash for prevention and treatment of stomatitis in women with hormone receptor positive breast cancer treated with everolimus

D. Moore, S. Hurvitz, Xiaoyan Wang, 2020, Therapeutic advances in medical oncology.

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases

S. Loi, G. Hortobagyi, L. Carey, 2022, JAMA oncology.

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.

Min Hwan Kim, Sung-Bae Kim, Chiun-Sheng Huang, 2022, The New England journal of medicine.

PIK3CA Status in Circulating Tumor DNA Predicts Efficacy of Buparlisib Plus Fulvestrant in Postmenopausal Women With Endocrine-resistant HR+/HER2- Advanced Breast Cancer: First Results From the Randomized, Phase III BELLE-2 Trial

J. Baselga, H. Iwata, W. Jonat, 2015 .

Neratinib Plus Capecitabine Provides a Glimmer of Hope for a Daunting Disease.

S. Hurvitz, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCN Guidelines® Insights: Breast Cancer, Version 4.2021.

Amy M. Sitapati, W. Gradishar, R. Aft, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

A multicenter, open-label phase II trial of dovitinib, a fibroblast growth factor receptor 1 (FGFR1) inhibitor, in FGFR1-amplified and nonamplified metastatic breast cancer (BC).

J. Baselga, F. André, M. Campone, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.

C. Isaacs, F. André, M. Riester, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.

Qingyuan Zhang, Kunwei Shen, Masakazu Toi, 2015, The Lancet. Oncology.

Abstract S4-06: Biological effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+, HER2- breast cancer

M. Press, M. Martín, E. Petru, 2017 .

Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

Thomas Bachelot, Florence Dalenc, Fabrice André, 2013, Clinical Cancer Research.

Human epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent disease

S. Hurvitz, R. Callahan, 2011, Current opinion in obstetrics & gynecology.

Dose intensification of chemotherapy for early breast cancer in the age of de-escalation

S. Hurvitz, 2019, The Lancet.

A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors

J. Desai, E. Rasmussen, M. Carducci, 2018, Investigational New Drugs.

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.

Sung-Bae Kim, E. Tokunaga, H. Iwata, 2019, The New England journal of medicine.

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Norikazu Masuda, Stephen Chia, Mark Clemons, 2017, The Lancet. Oncology.

Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer

S. Hurvitz, P. Drullinsky, 2020, Breast Cancer Research and Treatment.

Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer

D. Slamon, R. Beckmann, S. Hurvitz, 2018, Molecular Cancer Therapeutics.

New directions in the neoadjuvant treatment of HER2+ breast cancer

S. Hurvitz, E. Hobbs, 2015 .

Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT

C. Schnell, R. Finn, D. Slamon, 2014, Clinical Cancer Research.

Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer.

S. Hurvitz, Parvin F. Peddi, R. Shatsky, 2014, Cancer treatment reviews.

PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer

S. Hurvitz, Parvin F. Peddi, 2014, Journal of Neuro-Oncology.

Current approaches and future directions in the treatment of HER2-positive breast cancer.

R. Finn, Yufang Hu, S. Hurvitz, 2013, Cancer treatment reviews.

Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer.

S. Hurvitz, R. Kakkar, 2012, Breast cancer.

Breast Cancer : Targets and Therapy Role of lapatinib alone or in combination in the treatment of HER 2-positive breast cancer

S. Hurvitz, R. Kakkar, 2012 .

Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab.

F. André, M. Campone, J. Soria, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.

L. Chow, A. Bardia, N. Harbeck, 2018, The Lancet. Oncology.

93MO Overall survival (OS) results by age subgroup from the phase III MONALEESA-7 (ML-7) trial of premenopausal patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)

F. Cardoso, D. Tripathy, F. Franke, 2021 .

Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib

L. Chow, A. Bardia, N. Harbeck, 2021 .

Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study

Sung-Bae Kim, L. Chow, Chiun-Sheng Huang, 2020, Journal for ImmunoTherapy of Cancer.

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Sung-Bae Kim, S. Loi, Chiun-Sheng Huang, 2022, The Lancet.

Neratinib plus fulvestrant plus trastzuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial.

S. Loi, M. Burkard, R. Bose, 2022, Journal of Clinical Oncology.

Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpresing solid tumors: Results from two phase 1 clinical trials.

G. T. Budd, J. O’Shaughnessy, G. Budd, 2021, Journal of Clinical Oncology.

Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response

Jennifer L. Caswell-Jin, C. Curtis, J. Beechem, 2020, Nature Cancer.

Cycling cancer persister cells arise from lineages with distinct programs

A. Regev, M. Tabaka, K. Politi, 2021, Nature.

Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients

M. Buyse, J. Mackey, N. Robert, 2012, Clinical Cancer Research.

LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study

G. Curigliano, S. Verma, S. Im, 2021, Annals of Oncology.

Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1

Bing-he Xu, F. Ringeisen, Z. Shao, 2017, Breast Cancer Research.

In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response

J. Dering, R. Finn, D. Slamon, 2015, Breast Cancer Research and Treatment.

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

E. Winer, S. Loi, L. Carey, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCN Guidelines® Insights: Breast Cancer, Version 4.2021.

Amy M. Sitapati, W. Gradishar, R. Aft, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4.

S. Horvath, T. Graeber, I. Mellinghoff, 2016, Cell reports.

Harnessing the immune system in the battle against breast cancer

S. Hurvitz, E. Nakasone, Kelly E McCann, 2018, Drugs in context.

Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin’s lymphomas: a focus on FavId™

J. Timmerman, S. Hurvitz, 2005, Expert opinion on biological therapy.

Abstract P5-19-01: Randomized Phase III trial of afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one prior trastuzumab treatment: LUX-Breast 1

Chiun-Sheng Huang, Bing-he Xu, N. Harbeck, 2015 .

Abstract P5-19-07: Randomized Phase II trial of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab and/or lapatinib-based therapy: LUX-Breast 3

M. Espié, Sung-Bae Kim, A. Schneeweiss, 2015 .

Rational management of endocrine resistance in breast cancer

S. Hurvitz, R. Pietras, 2008, Cancer.

M. Irwin, P. Ganz, J. Bower, 2022, npj Breast Cancer.

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

Jennifer L. Caswell-Jin, A. Giuliano, C. Curtis, 2020, Nature Communications.

Genomic Profiling of Premenopausal HR+ and HER2– Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib

A. Bardia, N. Harbeck, D. Tripathy, 2021, JCO precision oncology.

Clinical performance of the DigniCap system, a scalp hypothermia system, in preventing chemotherapy-induced alopecia.

H. Rugo, R. D'Agostino, M. Melisko, 2015 .

A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy in patients with advanced breast cancer and a germline BRCA mutation: EMBRACA subgroups by age

W. Eiermann, H. Rugo, I. C. Tudor, 2018, The Breast.

nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.

S. Hurvitz, Christine Megerdichian, Yuliya B. Olimpiadi, 2014, Cancer treatment reviews.

Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis.

S. Loi, G. Hortobagyi, L. Carey, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs

H. Rugo, S. Swain, M. Cobleigh, 2019, Clinical Cancer Research.

Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09)

D. Slamon, S. Hurvitz, Xiaoyan Wang, 2018, Therapeutic advances in medical oncology.

A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib (BMN 673) in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO).

P. Fasching, M. Robson, A. Wardley, 2015 .

Predictive Biomarkers and Personalized Medicine Targeting FGFR with Dovitinib ( TKI 258 ) : Preclinical and Clinical Data in Breast Cancer

H. Rugo, M. Campone, M. Shi, 2013 .

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.

J. Mackey, W. Eiermann, T. Pintér, 2011, The Lancet. Oncology.

What's positive about 'triple-negative' breast cancer?

R. Finn, S. Hurvitz, 2009, Future oncology.

AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer

A. Bardia, H. Iwata, Z. Shao, 2022, Therapeutic advances in medical oncology.

Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial

Sung-Bae Kim, W. Gradishar, R. Bose, 2021, The oncologist.

Abstract PD5-01: Final results of NeoMONARCH: A phase 2 neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive (HR+), HER2 negative breast cancer (BC)

M. Press, M. Martín, E. Petru, 2018 .

Phase I Study of PD 0332991, a Novel, Oral, Cyclin-D Kinase (CDK) 4/6 Inhibitor in Combination with Letrozole, for First-Line Treatment of Metastatic Post-Menopausal, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer.

R. Finn, N. Shaik, J. Glaspy, 2009 .

Long-term Outcomes of Neoadjuvant Treatment of HER 2-Positive Breast Cancer

S. Hurvitz, Bingnan Zhang, 2016 .

A careful reassessment of anthracycline use in curable breast cancer

P. Fasching, A. Bardia, J. Crown, 2021, NPJ breast cancer.

Cycling cancer persister cells arise from lineages with distinct transcriptional and metabolic programs

A. Regev, M. Tabaka, J. Brugge, 2020, bioRxiv.

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

P. Fasching, E. Winer, P. V. van Dam, 2019, Clinical Cancer Research.

Final Results of a Phase II Trial Evaluating Trastuzumab and Bevacizumab as First Line Treatment of HER2-Amplified Advanced Breast Cancer.

D. Elashoff, R. Hermann, C. Vogel, 2009 .

Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation

W. Eiermann, I. C. Tudor, Y. Im, 2018 .

LBA14 Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study

P. Fasching, A. Bardia, S. Hurvitz, 2021, Annals of Oncology.

Abstract OT2-01-05: TRINITI-1: Ribociclib + everolimus (EVE) + exemestane (EXE) triplet combination in men or postmenopausal women with HR+, HER2– advanced breast cancer (ABC) following progression on a cyclin-dependent kinase (CDK) 4/6 inhibitor

A. Bardia, A. Clark, S. Moulder, 2017 .

Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.

L. Chow, A. Bardia, N. Harbeck, 2019, Journal of Clinical Oncology.

The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer

H. Rugo, S. Swain, D. Tripathy, 2014, BMC Cancer.

Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer

L. Bosserman, D. Slamon, B. Childs, 2014, SpringerPlus.

Can women with HER2-positive dnMBC be cured?

S. Hurvitz, F. Haji, 2021, Clinical Breast Cancer.

Finding the Sweet Spot in the Management of Early HER2+ Breast Cancer.

S. Hurvitz, 2021, JCO oncology practice.

Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer

J. Weidhaas, J. Hegde, M. Steinberg, 2017, Clinical breast cancer.

HER2-Positive Breast Cancer: Update on New and Emerging Agents

A. Drakaki, S. Hurvitz, 2015 .

Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates.

S. Hurvitz, D. Wong, 2014, Annals of translational medicine.

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine

S. Hurvitz, S. Sadeghi, O. Olevsky, 2014, Pharmacogenomics and personalized medicine.

Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential

S. Hurvitz, Parvin F. Peddi, 2014, Therapeutic advances in medical oncology.

Treatment of trastuzumab-refractory, HER2-positive metastatic breast cancer.

S. Hurvitz, 2014, Clinical advances in hematology & oncology : H&O.

Patient‐reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer

D. Miles, V. Diéras, J. Sohn, 2014, Cancer.

E. Perez, L. Amler, L. Gianni, 2014, Breast Cancer Research.

5001 ORAL Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (H+T) in Previously-untreated HER2-positive Metastatic Breast Cancer (MBC): Primary Results of a Randomized, Multicenter, Open-label Phase II Study (TDM4450g/BO21976)

E. Perez, L. Dirix, L. Gianni, 2011 .

Chemotherapy regimen choice and patient outcomes in early-stage triple-negative breast cancer: a retrospective analysis

S. Hurvitz, N. McAndrew, S. Ghafouri, 2022, Therapeutic advances in medical oncology.

Oncotype DX Recurrence Score in premenopausal women

S. Hurvitz, Shiliang Zhang, Kasey C. Fitzsimmons, 2022, Therapeutic advances in medical oncology.

Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

R. Bose, H. Rugo, C. Singer, 2022, Breast.

Innovations in targeted therapies for triple negative breast cancer.

S. Hurvitz, Kelly E McCann, 2020, Current opinion in obstetrics & gynecology.

Advances in Targeted Therapies for Triple-Negative Breast Cancer

S. Hurvitz, N. McAndrew, Kelly E McCann, 2019, Drugs.

A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC).

Sung-Bae Kim, A. Bardia, Chiun-Sheng Huang, 2015 .

De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry

H. Rugo, S. Swain, M. Cobleigh, 2019, The oncologist.

Antibody–drug conjugates: an emerging modality for the treatment of cancer

Mauricio Leal, Dhaval K Shah, A. Wahl, 2014, Annals of the New York Academy of Sciences.

Current status of therapeutic vaccines for non-Hodgkin's lymphoma

J. Timmerman, S. Hurvitz, 2005, Current opinion in oncology.

Predictive Biomarkers and Personalized Medicine Analysis of Fc g Receptor IIIa and IIa Polymorphisms : Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients

M. Buyse, J. Mackey, N. Robert, 2012 .

Phase I/II Study of Ipilimumab (MDX-010), an Anti-CTLA-4 Monoclonal Antibody, in Patients with Follicular Non-Hodgkin Lymphoma.

T. Habermann, S. Ansell, S. Geyer, 2006 .

7LBA Phase 1 dose-expansion study of AMG 900, a pan-Aurora kinase inhibitor, in adult patients with advanced taxane-resistant solid tumors

J. Desai, M. Carducci, B. Markman, 2014 .

Abstract GS2-05: First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial

A. Bardia, N. Harbeck, D. Tripathy, 2018 .

Abstract P1-14-03: ABRAZO: Exposure-efficacy and -safety analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in a phase 2 open-label trial

P. Fasching, M. Robson, L. Nguyen, 2018 .

Abstract CT128: Effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients (pts) with HER2+ early-stage breast cancer (eBC): the CONTROL trial

D. Tripathy, N. Iannotti, C. Barcenas, 2017 .

Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer

P. Fasching, T. Delea, J. O’Shaughnessy, 2021, Cancer management and research.

S. Verma, D. Tripathy, D. Yardley, 2016, BMC Cancer.

Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer

H. Wildiers, S. Hurvitz, P. Gilbar, 2021, Breast Cancer Research and Treatment.

Is weight-based IV dosing of trastuzumab preferable to SC fixed-dose in some patients? A systematic scoping review

C. Jackisch, H. Barham, V. Hanes, 2021, Breast.

LBA17 ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)

M. Piccart, L. Carey, A. Bardia, 2020 .

Targeted Therapy for Premenopausal Women with HR+, HER2− Advanced Breast Cancer: Focus on Special Considerations and Latest Advances

A. Bardia, S. Hurvitz, 2018, Clinical Cancer Research.

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).

E. Winer, S. Loi, L. Carey, 2020 .

Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2- breast cancer.

P. Fasching, A. Schneeweiss, J. García-Saenz, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study.

L. Carey, A. Bardia, H. Rugo, 2022, Journal of Clinical Oncology.

259P Weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancer

L. Pusztai, R. Nanda, J. O’Shaughnessy, 2021, Annals of Oncology.

Sacituzumab Govitecan in Metastatic Breast Cancer. Reply.

A. Bardia, H. Rugo, S. Hurvitz, 2021, The New England journal of medicine.

Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer

Sung-Bae Kim, J. Baselga, E. Tokunaga, 2021 .

Abstract PD3-14: Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer

Marilyn M. Li, L. Pusztai, R. Nanda, 2018 .

Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer—Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy

A. Schneeweiss, A. Tsimberidou, M. Ocker, 2019, Cancers.

Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer.

S. Hurvitz, Bingnan Zhang, 2016, Clinical advances in hematology & oncology : H&O.

Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer.

S. Hurvitz, Parvin F. Peddi, 2013, Future oncology.

Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial

H. Burris, D. Yardley, G. Jerusalem, 2018, JAMA oncology.

Symptom Burden and Quality of Life among Women with HER2+ Metastatic Breast Cancer

D. Tripathy, J. Menzin, K. Lang, 2015, The breast journal.

Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab

F. André, M. Campone, R. O'Regan, 2008 .

Evolving options for the treatment of metastatic breast cancer: progression-free survival as an endpoint.

S. Hurvitz, 2011, Cancer treatment reviews.

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

A. Bardia, H. Rugo, R. Leon-Ferre, 2022, Breast Cancer Research and Treatment.

Oncological care organisation during COVID-19 outbreak

J. Machiels, H. Rugo, H. Wildiers, 2020, ESMO Open.

Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).

A. Bardia, H. Rugo, S. Loibl, 2021 .

Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2− advanced breast cancer

N. Harbeck, Y. Im, D. Tripathy, 2022, Therapeutic advances in medical oncology.

Abstract PD13-07: Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer

L. Carey, A. Bardia, H. Rugo, 2021 .

162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer

C. Shapiro, P. Debruyne, S. Hurvitz, 2022, Annals of Oncology.

Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.

Sung-Bae Kim, E. Tokunaga, Yeon-Hee Park, 2021 .

Abstract P3-07-14: Increasing proportion of de novo compared with recurrent HER2-positive metastatic breast cancer: Early results from the systemic therapies for HER2-positive metastatic breast cancer registry study

H. Rugo, S. Swain, M. Cobleigh, 2015 .

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer

Sung-Bae Kim, W. Gradishar, H. Wildiers, 2021, Clinical Cancer Research.

Abstract GS3-06: Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

L. Carey, A. Bardia, H. Rugo, 2021 .

Abstract PS11-09: Impact ofUGT1A1status on the safety profile of sacituzumab govitecan in the phase 3 ASCENT study in patients with metastatic triple-negative breast cancer

M. Piccart, L. Carey, A. Bardia, 2021 .

SGNLVA-001: A phase I open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer.

L. Pusztai, H. Rugo, R. Nanda, 2020 .

Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results.

A. Bardia, A. DeMichele, L. Hart, 2019, Journal of Clinical Oncology.

Validation of the NCI patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in women receiving treatment for metastatic breast cancer.

L. Minasian, E. Basch, A. Bennett, 2012 .

Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC).

L. Carey, A. Bardia, H. Rugo, 2021 .

168P Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: Findings from the phase III ASCENT study

A. Bardia, J. O’Shaughnessy, V. Diéras, 2022, Annals of Oncology.

Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)

D. Slamon, M. Press, A. Prat, 2023, Breast Cancer Research.

Abstract PD3-06: Association of intrinsic subtypes with pathological complete response (pCR) in the KRISTINE neoadjuvant phase 3 clinical trial in HER2-positive early breast cancer (EBC)

M. Press, A. Prat, G. Phillips, 2018 .

Abstract PD2-06: Efficacy of abemaciclib based on genomic alterations detected in baseline circulating tumor DNA from the MONARCH 3 study of abemaciclib plus nonsteroidal aromatase inhibitor

M. Goetz, M. Campone, S. Johnston, 2020 .

Abstract 4150: Anti-tumor activity of the PI3K/mTOR pathway inhibitors alpelisib (BYL719) and everolimus (RAD001) in xenograft models of acquired resistance to CDK-4/6 targeted therapy

D. Slamon, S. Scherer, S. Hurvitz, 2017 .

Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.

Sung-Bae Kim, H. Iwata, G. Curigliano, 2022, Journal of Clinical Oncology.

Abstract GS3-01: Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03

Sung-Bae Kim, H. Iwata, Yeon-Hee Park, 2022, Cancer Research.

TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer.

A. Bardia, L. Spring, S. Hurvitz, 2021 .

Abstract GS1-03: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01)

Sung-Bae Kim, E. Tokunaga, H. Iwata, 2020 .

236P Subgroup analysis by disease history and prior treatments of patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1)

S. Hurvitz, E. Hamilton, G. Curigliano, 2022, Annals of Oncology.

Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).

E. Winer, S. Loi, G. Hortobagyi, 2021 .

DESTINY-Changing Results for Advanced Breast Cancer.

S. Hurvitz, 2022, The New England journal of medicine.

Abstract OT1-14-01: Zanidatamab in combination with ALX148 in advanced human epidermal growth factor receptor 2 (HER2)-expressing cancers, including breast cancer: A phase 1b/2, multicenter, open-label, dose-finding and cohort-expansion study (ZWI-ZW25-204)

F. Meric-Bernstam, A. Brufsky, S. Hurvitz, 2022, Cancer Research.

Abstract GS1-01: Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB)

R. Greil, E. Winer, S. Loi, 2020 .

Do all patients with cancer experience fatigue? A longitudinal study of fatigue trajectories in women with breast cancer

M. Irwin, P. Ganz, J. Bower, 2021, Cancer.

Systemic Therapy for Early- and Late-Stage, Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer.

S. Hurvitz, N. McAndrew, 2023, Hematology/oncology clinics of North America.

Testing a biobehavioral model of fatigue before adjuvant therapy in women with breast cancer

S. Cole, P. Ganz, J. Bower, 2019, Cancer.

BOLERO-1: A randomized, phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel as first-line therapy in women with HER2-positive (HER2+), locally advanced or metastatic breast cancer (BC).

M. Buyse, F. André, H. Burris, 2012 .

138O CNS metastases in HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan: DESTINY-Breast01 subgroup analyses

Young-Ae Park, G. Jerusalem, S. Hurvitz, 2020 .

NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC).

P. Fasching, G. Hortobagyi, S. Verma, 2019, Journal of Clinical Oncology.

Phase I study of PD 0332991, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole for first-line treatment of patients with ER-positive, HER2-negative breast cancer.

R. Finn, J. Glaspy, S. Hurvitz, 2010 .

O82 A phase 1 dose escalation study of PRS-343, a HER2/4–1BB bispecific molecule, in patients with HER2-positive malignancies

A. Tolcher, L. Matis, I. Bruns, 2020, Journal of Immunotherapy for Cancer.

272P Outcomes of patients (pts) who had received prior platinum (PP) therapy in the phase III EMBRACA trial of talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC)

S. Hurvitz, T. Usari, K. Lee, 2021, Annals of Oncology.

EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment.

W. Eiermann, H. Rugo, I. C. Tudor, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract PD13-08: First-in-human safety and activity of ARV-471, a novel PROTAC® estrogen receptor degrader, in ER+/HER2- locally advanced or metastatic breast cancer

R. Gedrich, S. Hurvitz, L. Vahdat, 2022, Cancer Research.

Impact of a Palliative Care Nurse Practitioner in an Oncology Clinic: A Quality Improvement Effort

N. Wenger, L. Rosen, A. Drakaki, 2021, JCO oncology practice.

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer

S. Loi, G. Hortobagyi, A. Bardia, 2023, Therapeutic advances in medical oncology.

Costs associated with chemotherapy-related complications in the treatment of metastatic breast cancer in a real-world setting.

S. Hurvitz, E. Wu, A. Yu, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC).

E. Perez, V. Valero, V. Smirnov, 2010 .

Genetic polymorphisms and correlation with treatment induced cardiotoxicity and prognosis in breast cancer patients.

P. Fasching, R. Weinshilboum, Liewei Wang, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Perspectives and attitudes on the use of adjuvant chemotherapy and trastuzumab in older adults with HER-2+ breast cancer: a survey of oncologists.

A. Naeim, S. Bhatia, S. Pal, 2009, The oncologist.

Individual attributions of living longer with HER2+ metastatic breast cancer: Findings from a community web-based survey.

D. Tripathy, J. Menzin, M. Sussman, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)

A. Bardia, H. Rugo, A. DeMichele, 2021, Clinical Cancer Research.

In-depth gene expression analysis of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial.

A. Bardia, N. Harbeck, S. Kuemmel, 2019, Journal of Clinical Oncology.

ARV-471, an estrogen receptor (ER) PROTACdegrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study.

R. Nanda, R. Gedrich, S. Hurvitz, 2022, Journal of Clinical Oncology.

Statistical controversies in clinical research: statistical significance-too much of a good thing ….

M. Buyse, W. Eiermann, F. André, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

metastatic breast cancer : latest evidence and ongoing studies The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive

S. Hurvitz, R. Kakkar, 2012 .

The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer

H. Rugo, S. Swain, D. Tripathy, 2014, BMC Cancer.

Is the duration of adjuvant trastuzumab debate still clinically relevant?

S. Hurvitz, 2019, The Lancet.

Exploratory Analysis of the Relationship Between Her2 Expression (BY QRT-PCR) and Efficacy with First-Line Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (HT) in a Randomized Phase 2 Study of Patients (PTS) with HER2-Positive MBC

E. Perez, L. Amler, L. Gianni, 2012 .

Abstract GS3-03: GS3-03 ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study

A. Tan, R. Nanda, P. Munster, 2023, Cancer Research.

Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.

P. Fasching, A. Bardia, Yeon-Hee Park, 2022, Journal of Clinical Oncology.

Effect of prophylaxis on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Phase II CONTROL trial.

R. Bose, H. Rugo, D. Tripathy, 2019, Journal of Clinical Oncology.

M. Piccart, L. Carey, A. Bardia, 2021, Annals of Oncology.

Abstract GS2-01: High levels of interferon-response gene signatures are associated withde novoand acquired resistance to CDK4/6 inhibitors in ER+ breast cancer

R. Schiff, J. Reis-Filho, B. Weigelt, 2020 .

Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health Records

S. Swain, S. Hurvitz, A. Knott, 2023, JCO oncology practice.

Can Women With HER2-Positive Metastatic Breast Cancer Be Cured?

S. Hurvitz, F. Haji, 2021, Clinical breast cancer.

LUX-breast 1: Randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment.

Chiun-Sheng Huang, Bing-he Xu, N. Harbeck, 2012 .

NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.

W. Gradishar, R. Aft, M. Dwyer, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

First-in-human phase 1/1b expansion of PMD-026, an oral RSK inhibitor, in patients with metastatic triple-negative breast cancer.

M. Beeram, A. Patnaik, S. Dunn, 2021 .

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Sung-Bae Kim, Yeon-Hee Park, G. Jerusalem, 2022, Cancer discovery.

525O A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies

A. Tolcher, G. Ku, A. El-Khoueiry, 2020, Annals of Oncology.

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

352TiP EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2–positive (HER2+) advanced breast cancer (ABC)

S. Chandarlapaty, H. Rugo, M. Lacouture, 2020 .

Abstract GS2-02: GS2-02 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03

H. Iwata, Bing-he Xu, G. Curigliano, 2023, Cancer Research.

Abstract P6-07-09: Biomarker analysis from the neoadjuvant KRISTINE study in HER2-positive early breast cancer (EBC)

Jianming Xu, M. Press, G. Phillips, 2017 .

Abstract GS2-03: GS2-03 TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer

A. Bardia, S. Dakhil, M. Press, 2023, Cancer Research.

Acquired genomic alterations in circulating tumor DNA from patients receiving abemaciclib alone or in combination with endocrine therapy.

M. Goetz, M. Campone, S. Johnston, 2020 .

TARGETING PATHWAYS, EFFICACY, AND COMBINATIONS Transforming Immuno-Oncology Across Solid Tumors Join us live in Chicago or live streaming webcast from anywhere!

A. Pavlick, A. Drakaki, S. Hurvitz, 2015 .

Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial.

S. Loi, G. Hortobagyi, A. Bardia, 2023, Journal of Clinical Oncology.

RAD001 (everolimus) in combination with weekly paclitaxel and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab: a multicenter phase I clinical trial.

F. André, M. Campone, M. Naughton, 2009 .

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

S. Loi, M. Burkard, R. Bose, 2023, Annals of Oncology.

Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.

Zheng-Yi Zhou, S. Hurvitz, E. Wu, 2014, The Oncologist.

Early efficacy evaluation of ORIN1001, a first in class IRE1 alpha inhibitor, in advanced solid tumors.

T. Pluard, A. Elias, N. Gabrail, 2023, Journal of Clinical Oncology.

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Shaughnessy, O. J., L. Carey, 2022 .

Abstract PS9-02: Neratinib + capecitabine sustains health-related quality of life (HRQoL) while improving progression-free survival (PFS) in patients with HER2+ metastatic breast cancer and ≥2 prior HER2-directed regimens

Sung-Bae Kim, W. Gradishar, R. Bose, 2021 .

How are quality of life and work productivity associated with living longer with HER2+ metastatic breast cancer?

D. Tripathy, M. Sussman, S. Hurvitz, 2017 .

Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.

A. Bardia, Yeon-Hee Park, D. Yardley, 2023, The Lancet. Oncology.

Abstract P6-17-11: The small molecule inhibitor of HER2, tucatinib, has potent and highly selective activity in preclinical modes of HER2-driven cancer

S. Hurvitz, D. Slamon, Tong Luo, 2019, Poster Session Abstracts.

293P Impact of tucatinib on progression free survival in patients with HER2+ metastatic breast cancer and stable or active brain metastases

G. Hortobagyi, R. Murthy, S. Loibl, 2020 .

Abstract CT092: A phase II study of neoadjuvant abemaciclib (LY2835219) in postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer (neoMONARCH)

J. Schilder, Miguel Martín, S. Hurvitz, 2016 .

Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma

T. Habermann, S. Ansell, I. Lowy, 2009, Clinical Cancer Research.

Current approaches and future directions in the treatment of HER2-positive breast cancer.

R. Finn, Yufang Hu, S. Hurvitz, 2013, Cancer treatment reviews.

Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR þ /HER2 (cid:2) Breast Cancer A C

D. Slamon, S. Hurvitz, S. Wijayawardana, 2019 .

D. Miles, V. Diéras, J. Sohn, 2014, Cancer.

Dose intensification of chemotherapy for early breast cancer in the age of de-escalation

S. Hurvitz, 2019, The Lancet.

MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4.

S. Horvath, T. Graeber, I. Mellinghoff, 2016, Cell reports.

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Sung-Bae Kim, S. Loi, Chiun-Sheng Huang, 2022, The Lancet.

A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer.

M. Piccart, L. Carey, A. Bardia, 2021, Future oncology.

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine

S. Hurvitz, S. Sadeghi, O. Olevsky, 2014, Pharmacogenomics and personalized medicine.

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

M. Piccart, L. Carey, A. Bardia, 2021, New England Journal of Medicine.

Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer

J. Weidhaas, J. Hegde, M. Steinberg, 2017, Breast Cancer Research and Treatment.

Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer

M. Goetz, A. Llombart-Cussac, S. Hurvitz, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Ribociclib plus Endocrine Therapy in Early Breast Cancer.

G. Hortobagyi, D. Yardley, M. Ruíz-Borrego, 2024, The New England journal of medicine.

Primary dural marginal zone lymphoma in a woman with inflammatory breast cancer.

J. Said, S. Hurvitz, Heather S. Lewin, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recent progress in antibody-drug conjugate therapy for cancer.

S. Hurvitz, 2022, Nature cancer.

Use of a Shared Mental Model by a Team Composed of Oncology, Palliative Care, and Supportive Care Clinicians to Facilitate Shared Decision Making in a Patient With Advanced Cancer.

N. Wenger, A. Coscarelli, S. Hurvitz, 2016, Journal of oncology practice.

Final overall survival (OS) and safety analyses of RIBBON-2, a randomized phase III trial of bevacizumab (BEV) versus placebo (PL) combined with second-line chemotherapy (CT) for HER2-negative BEV-naive metastatic breast cancer (MBC).

E. Perez, V. Valero, H. Rugo, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.